Failure of AstraZeneca's AZD4041 a Blow for Non-opioid OUD Treatments
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
Astrazeneca (AZN.US) combination therapy Truqap phase 3 trial results are positive.
Astrazeneca (AZN.US) announced today the positive results of the CAPItello-281 Phase 3 clinical trial.
Astrazeneca's Capivasertib for prostate cancer has successfully completed Phase III trials, and the outlook for Kairui Pharmaceutical-B (2105.HK) AKT inhibitors is bullish.
On November 25th, AstraZeneca announced the success of its AKT inhibitor Capivasertib in the phase III CAPItello-281 study for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Following the approval and launch of Capivasertib for breast cancer indications, this study further confirmed the clinical value of AKT inhibitors. AKT inhibitors, as drugs that have shown potential in multiple cancers such as breast cancer, prostate cancer, and ovarian cancer, have a very broad market outlook. In recent years, an increasing number of pharmaceutical companies have begun to pay attention to AKT inhibitors.
AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
loading...
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
